Literature DB >> 1553344

Determination of lidocaine concentrations in skin after transdermal iontophoresis: effects of vasoactive drugs.

J E Riviere1, N A Monteiro-Riviere, A O Inman.   

Abstract

The purpose of this study was to investigate the effect of vasoactive drugs on transdermal lidocaine inotophoresis by measuring the concentrations of radiolabeled lidocaine which has penetrated the skin. Previous studies had demonstrated that coinotophoresis of vasoactive drugs could modulate the transcutaneous flux of lidocaine and suggested that a dermal depot of lidocaine was involved. To address this, lidocaine hydrochloride (14C) was iontophoresed in vivo in anesthetized weanling pigs either alone or with the vasodilator tolazoline or the vasoconstrictor norepinephrine. Tissue cores under the active electrode were then collected, quick-frozen, and sectioned on a cryostat, and then the radioactivity was determined in each 40-microns section. Coiontophoresis with norepinephrine resulted in increased concentrations of lidocaine in skin up to a depth of 3 mm. These concentrations decreased to lidocaine-alone levels after a 4-hr washout. Tolazoline decreased tissue concentrations of lidocaine. Concentrations were intermediate when lidocaine alone was administered. These studies support the hypothesis that coiontophoresis of vasoactive drugs modulates the transdermal delivery of lidocaine, in part by altering the cutaneous "depot."

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1553344     DOI: 10.1023/a:1018985323001

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  3 in total

1.  Effects of vasoactive drugs on transdermal lidocaine iontophoresis.

Authors:  J E Riviere; B Sage; P L Williams
Journal:  J Pharm Sci       Date:  1991-07       Impact factor: 3.534

2.  Quantitative determination of percutaneous absorption of radiolabeled drugs in vitro and in vivo by human skin.

Authors:  H Schaefer; G Stüttgen; A Zesch; W Schalla; J Gazith
Journal:  Curr Probl Dermatol       Date:  1978

3.  Altered epidermal morphology secondary to lidocaine iontophoresis: in vivo and in vitro studies in porcine skin.

Authors:  N A Monteiro-Riviere
Journal:  Fundam Appl Toxicol       Date:  1990-07
  3 in total
  8 in total

Review 1.  Trials and tribulations of skin iontophoresis in therapeutics.

Authors:  Matthieu Roustit; Sophie Blaise; Jean-Luc Cracowski
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 2.  Transdermal iontophoresis. Pharmacokinetic considerations.

Authors:  P Singh; H I Maibach
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

3.  Transdermal delivery by iontophoresis.

Authors:  Swati Rawat; Sudha Vengurlekar; B Rakesh; S Jain; G Srikarti
Journal:  Indian J Pharm Sci       Date:  2008-01       Impact factor: 0.975

4.  Topical penetration of piroxicam is dependent on the distribution of the local cutaneous vasculature.

Authors:  N A Monteiro-Riviere; A O Inman; J E Riviere; S C McNeill; M L Francoeur
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

5.  Effect of electroporation on transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH) in vitro.

Authors:  D B Bommannan; J Tamada; L Leung; R O Potts
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

6.  Transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH): effect of repeated administration.

Authors:  M C Heit; N A Monteiro-Riviere; F L Jayes; J E Riviere
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

7.  Lateral iontophoretic solute transport in skin.

Authors:  P M Lai; Y G Anissimov; M S Roberts
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

8.  Transdermal penetration of vasoconstrictors--present understanding and assessment of the human epidermal flux and retention of free bases and ion-pairs.

Authors:  Sheree E Cross; Melanie J Thompson; Michael S Roberts
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.